Patient description: The patient is a 33-year-old woman complained of fatigue, weight gain and abnormal spotting between menses. No hirsutism or nipple discharge was detected. Her BMI was 34. Her lab results were remarkable for high TSH level (13 mU/L) and low free T4 level (0.2 ng/dl). Her anti-TPO levels were extremely high (120 IU/ml). She was diagnosed with Hashimoto's thyroiditis. Her aunt, brother and mother have the same disease. After starting 250 mcg Levothyroxine per day, her symptoms improved significantly and her periods are normal. She is still overweight with BMI of 31. Her most recent thyroid profile revealed all results except for anti-TPO within the normal range: TSH: 2.35 mU/L Free T4: 2.7 ng/dl Anti-TPO: 75 IU/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Hepatocellular Carcinoma BCLC Stage A Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma Metastatic Hepatocellular Carcinoma PRE-REGISTRATION: Age >= 18 years PRE-REGISTRATION: Disease characteristics Radiologically confirmed hepatocellular carcinoma (HCC) that is not eligible for curative resection, transplantation, or ablative therapies Received at least one prior systemic treatment for HCC NOTE: Prior radiation, chemoembolization, radioembolization or other local ablative therapies or hepatic resection are permitted PRE-REGISTRATION: Measurable disease by any imaging modality as defined by Response Evaluation in Solid Tumors (RECIST) 1.1 in at least one site not previously treated with radiation or liver directed therapy (including bland, chemo- or radio-embolization, or ablation) NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible PRE-REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 PRE-REGISTRATION: Child-Pugh scores of =< 7 (Child-Pugh A or B7) PRE-REGISTRATION: Barcelona Clinic Liver Cancer Stage (BCLC) stage A, B, or C  PRE-REGISTRATION: Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy PRE-REGISTRATION: Prior organ transplantation PRE-REGISTRATION: History of untreated brain metastasis PRE-REGISTRATION: History of hepatitis B (HBV) and viral load >=100 IU/mL NOTE: Patients who have received antiviral therapy and have viral load < 100 IU/mL are eligible PRE-REGISTRATION: History and/or current evidence of any of the following disorders Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens